Tuesday, May 23, 2017

Global Private Group, a private equity and project finance firm focused on worldwide investments, has made a USD 56 million investment to take a majority stake in a Central American corporate and personal fleet management company. 
 Global Private Group, a private equity and project finance firm focused on worldwide investments, has made a USD 56 million investment to take a majority stake in a Central American corporate and personal fleet management company. 
 Global Private Group, a private equity and project finance firm focused on worldwide investments, has made a USD 56 million investment to take a majority stake in a Central American corporate and personal fleet management company. 
 Global Private Group has made a USD 56 million investment to take a majority stake in a Central American corporate and personal fleet management company. 


Global Private Group, a private equity and project finance firm focused on worldwide investments, has made a USD 56 million investment to take a majority stake in a Central American corporate and personal fleet management company. The car rental sector in Central America grew by 19% in 2015 to USD3.1 billion, and has grown at a compound annual growth rate of 11% since 2003, according to the ABLA, the Brazilian Car Rental Association.
 
Partner of Global Private Group says: “As automobile penetration grows in Central America, we identified corporate fleet management as the more scalable business model within the car rental sector. The fleet management company, with its demonstrated record of growth and excellent customer service is the ideal company for our investment into this burgeoning sector. The company boasts a lean business model and is prudently leveraged, ensuring that our capital injection is used for growth instead of paying down debt.” Founded in 2008, the fleet management company currently operates a fleet of around 3,400 vehicles and focuses on the high growth, high margin, corporate fleet management market. The company expects to increase EBITDA by 80% in 2017 in comparison to 2016. 
 



Monday, May 22, 2017

Global Private Group, a private equity and project finance firm, has refinanced the debt of a Luxembourg based commercial asset management firm to the tune of EUR 251 million.

The commercial asset management firm has currently a strong mix of corporate tenants including leading accounting firm, major law firms and airline headquarters. One of the buildings is currently going through an active leasing process with over 10,000 sq m available to let; new tenants are expected to be secured, returning the asset to full occupancy, by the end of the year. Comprising a total area of over 48,000 sq m, the office building is located just South of Luxembourg City, offering easy access to international motor routes connecting to France, Belgium and Germany. Both the city centre and the airport are less than 10 minutes from the property by car. Constructed in 2006, the building achieved a ‘Very Good’ certification for asset and building management in 2014. Chief executive officer of the Company says: “We are delighted to have successfully refinanced this prime office building with Global Private Group. This transaction provides our firm with funding diversification as well as the potential for future financing with Global Private Group. Our Firm has been active in the Benelux region, which remains a target market for the group, for over 14 years.” “Global Private Group is extremely pleased to be working with the commercial asset management firm on refinancing this high-quality office building in Luxembourg. We see strong value in the asset and fully support the management team in their strategy to lease the available space in the property.”

Global Private Group has invested in Biopharmaceutical Company dedicated to the development of enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than forty rare inherited diseases

(1888PressRelease) May 22, 2017 - Series D financing round for the company raised USD 49.5M, Global Private Group was the sole arranger. The current fund will enable Biopharmaceutical Company to advance its lead ERT treatment for Pompe disease from preclinical stages through to the end of phase I/II, as well as further preclinical development of other ERTs. Pompe disease (also called Glycogen storage disease type II or acid maltase deficiency) is a rare, serious disease in which acid alpha-glucosidase enzyme deficiency leads to glycogen accumulation and muscle and nerve cells damage. If untreated, the infantile form is fatal - often before one year of age - due to cardiorespiratory failure. The Biopharmaceutical Company has developed a proprietary platform for the production of therapeutic proteins with homogenous, human sugar structures using the yeast Yarrowia lipolytica. Based on this platform, The Biopharmaceutical Company can produce human lysosomal enzymes with 3-15 times the amount of mannose 6-phosphate, the essential targeting sugar structure which facilitates effective enzyme uptake and localization, obtained in current commercial processes. The substantial enhanced levels of the natural targeting mechanism can deliver more than a 20-fold improvement in cellular uptake without altering the naturally occurring protein enzyme. Based on experience at 1,000 litre scale with its simple batch production process, The Biopharmaceutical Company believes that it can scale production up to 100,000 litres if necessary - dramatically altering the production economics of these products. Due to its proven versatility the Y. lipolytica platform not only enables robust and consistent production of lysosomal enzymes but also of a range of other human glycoproteins, including antibodies. CEO of The Biopharmaceutical Company says: "We are pleased to have Global Private Group join existing investor New Science Ventures. Global Private Group's reputation as respected, experienced investors will provide us with the support necessary to advance our exciting pipeline towards the clinic. The Biopharmaceutical Company is now well positioned to progress our research into clinical trials in Pompe disease in order to explore the potential benefits of our technology in people with this debilitating and potentially fatal disorder." Global Private Group is one of the largest and most experienced project finance groups in the world compromising more than 300 dedicated specialists in our offices worldwide who are fully qualified to provide financial services and products. Stable financing, efficient execution, expert solutions and customer service are how we help clients succeed. Our broad range of lending products in the areas of corporate lending and investment banking, combined with access to strong capital base; allows us to execute financing that supports your business objectives. Our deal professionals' industry expertise and attention to your goals during every step of the loan process allows us to offer solutions that help you achieve success. http://www.globalprivategroup.com

Sunday, May 21, 2017

World Bank predicts 2.7% global economic growth in 2017

Growth acceleration For emerging market and developing economies, the rise in interest rates in the US and the strengthening dollar also led to a "notable tightening of financing conditions" - which means credit that is either more expensive or harder to get. But the Bank still expects growth to accelerate in these countries, partly due to higher commodity prices, such as oil and metals, which many of them export. The Bank's economists also expect the slowdown in two large emerging economies, Brazil and Russia, to come to an end. For the developed economies the Bank forecasts continued weak growth of around 1.8%. That would be slightly better than 2016, but still slow compared to the period before the crisis. Uncertainty about future policies has increased following the British referendum on the European Union and, potentially especially significant for the global economy, Donald Trump's victory in the US Presidential election. The report includes an analysis of why the US matters so much to the rest of the world in terms of extensive trade and financial links. It notes that there is a great deal of uncertainty about just what policies Mr Trump's administration will pursue in office.

In Rural Bangladesh, Solar Power Dents Poverty

KAKHIN BIMILE, Bangladesh — Kismat Ali is a 33-year-old mason living in Kakhin Bimile, a village a few hours drive from Dhaka, Bangladesh’s crowded capital. He lives in a large brick home on a dirt road with his wife, son, parents and five brothers. This semirural area is off the main electrical grid, so residents rely on kerosene lamps and electricity from wires strung across the village to a noisy privately owned diesel generator. It runs about five hours each night. But Mr. Ali has a new source of electricity he can turn to: solar panels on his corrugated metal roof. In his home, he flicks a light switch and a bare bulb glows from the ceiling. Mr. Ali proudly switches on a fan that stirs the stultifying summer air. He says he wants to have a television one day, but is waiting for an LED TV that would consume less energy than models available now.

Saturday, May 20, 2017

http://www.military-technologies.net/2017/04/13/global-private-group-successfully-agented-and-syndicated-over-usd2-billion-in-30-deals/

Global Private Group successfully agented and syndicated over USD2 billion in 30 deals. Global Private Group stands among a limited number of upper market lenders who have the ability to loan up to USD25 Billion and underwrite and syndicate transactions up to USD50 Billion, providing a unique competitive advantage.

http://rezul.com/news/10330498

Global Private Group has advised Biopharmaceutical Company on the raising of EUR 270 million through a placing of new shares Global Private Group acted as reporting accountant on the fund raising, and sole arranger. NEW YORK - May 2, 2017 - Rezul -- Global Private Group has advised Biopharmaceutical Company on the raising of EUR 270 million through a placing of new shares. Global Private Group acted as reporting accountant on the fund raising, and sole arranger. The Biopharmaceutical Company is a life sciences company providing services and technologies enabling the development and manufacture of biopharmaceutical products. Since its admission the business has grown significantly organically and via acquisition in both the Europe and US. The Biopharmaceutical Company intends to use the proceeds from the placing to acquire a Chemistry Research Solutions Company, a specialist contract chemistry and bio-conjugation company with operations in Europe and US, and to back further research and development work.

Stay Connected

1-866-949-7323

Contact Us

» Email: info@globalprivategroup.com

Loan Application

Global Private Group provides a preliminary online application form which is used to determine elegibility for any of our programs. Your information is safe, secure, and will only be used to provide you a better service. To proceed to the form, please click the icon below.

Fill out the application form.